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ABSTRACT
Psoriasis is a hyperproliferative, autoimmune skin disorder. There are several therapeutic agents used topically and systemically, but they have 
adverse effects. It has been reported that beta-blockers intensify psoriatic plaque and decrease the concentration of intracellular cyclic adenosine 
monophosphate (cAMP). In the psoriatic epidermis, the level of cAMP decreases. Caffeine is a methylxanthine that inhibits phosphodiesterase 
enzyme and results in a higher concentration of intracellular cAMP. Adding caffeine to topical skin treatments would be a simple way to reduce 
inflammation in patients with psoriasis. Furthermore, phenolic acids like chlorogenic acid (3-CQA) have recently gained substantial attention due to 
their various biological and pharmacological effects. Curcumin (dihydroferuloyl-methane) is a flavonoid that possesses anti-inflammatory, antitumor, 
and antioxidative properties. Cell proliferation arrest is caused by curcumin and apoptosis is induced in several types of human and animal cells. 
Imiquimod-induced murine psoriasis is most used animal models to study this disease, due to the usage of healthy mice. Xenotransplants of human 
psoriatic skin in immunodeficient mice were the first approach for the association of immunologic problems with the development of psoriasis and 
have been also useful for the evaluation of new therapeutic agents.
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INTRODUCTION
Psoriasis is a chronic autoimmune inflammatory disease which is 
characterized by epidermal hyperplasia and inappropriate immune 
activation that affects both skin and joints. Multiple erythematous 
scaly lesions are characteristic features in the skin where well-defined 
plaques arise mainly in the scalp, knees, elbows, lower back, and 
navel. It may also spread throughout the body in a systemic way as 
erythroderma [1-3]. In the joints, it attacks the insertions of tendons 
leading to pain and inflammation followed by a joint deformity, 
especially in small joints [2]. It can occur in both sexes and any age 
group, but psoriatic arthritis usually develops between the ages of 
30 and 50 years [4]. It is an organ-specific autoimmune disease, i.e., a 
clinical syndrome caused by the activation of T cells and B cells, or both, 
in the absence of an ongoing infection or other distinct cause, that is 
triggered by an activated cellular immune system [5-10]. It is similar 
to other immune-mediated diseases such as rheumatoid arthritis, 
multiple sclerosis, Crohn’s disease, and juvenile-onset diabetes. Since 
psoriasis occurs in an accessible organ, it has been possible to study 
its cellular and genomic features in tremendous detail compared with 
those of other human autoimmune diseases [11].
Clinical manifestations of psoriasis are different. Types of psoriasis 
include plaque, guttate, pustular, and erythrodermic. Any part of the 
skin may be affected; the most common sites are the scalp, elbows, 
knees, shins, umbilicus, sacrum, and genitalia. Plaques may range 
in various sizes. Guttate psoriasis is characterized by small scaly 
erythematous papules, usually occurring in adolescents or younger 
adults often after infectious conditions. Erythrodermic psoriasis 
affects more than 90% of body surface with scales and intense 
subacute or chronic erythema and deprived health. It may occur due 
to deterioration of psoriasis plaques or generalized pustular form 
and possibly as an early symptom of the disease. Pustular psoriasis 
can have a local or generalized presentation. Mostly, it occurs in 
patients with psoriasis plaque, after exposure with irritating factors, 
such as hypocalcemia, interruption of systemic corticosteroid therapy, 
untimely topical therapy, and infection [3,4,12].
IMMUNOPATHOGENESIS OF PSORIASIS
The immunopathogenesis of psoriasis involves changes in the innate 
(dendritic cells and keratinocytes) and acquired (T lymphocytes) 
immune system. Growth factors, chemokines, and cytokines are 
produced by cells of the innate immune system when activated. These 
act on cells of the acquired immune system and vice versa [13,14].
Usually, the skin regeneration takes around 28–30 days with the 
formation of fresh cells on its lower layer, while the old ones migrate 
to the top layer of skin falling in an unnoticed way. In psoriasis, the cell 
cycle changes at once and can be reduced to 4 days. These altered cells 
gather and form whitish plates with erythroderma originating typical 
lesions of the disease [15].
There is activation of the dendritic cells and keratinocytes. Several 
environmental factors such as mechanical trauma, infections, drugs, 
and emotional anxiety are considered trigger factors of the disease [1]. 
For example, the mechanical strain can activate keratinocytes in a 
similar manner as that of binding of infectious agents antigens to 
Toll-like receptors of dendritic cells and keratinocytes. This leads 
to their activation by producing several cytokines, chemokines, 
tumor necrosis factor (TNF)-α, growth factors, and interleukin 1 
(IL-1) [14]. In addition, interaction of T cells with dendritic cells 
and macrophages forming new “immunological synapse” takes 
place in the dermis. This interaction leads to the assembly of 
several cytokines, which retain and intensify the inflammatory 
process [13]. IL-12 and IL-23 are produced by the dendritic cells 
and the activated macrophages. The proliferation of Th1 and Th17 is 
promoted by IL-12. Increase of Th1 and Th17 in psoriasis condition 
leads to the reduction in regulatory T cells [16]. The dendritic cells 
present in dermal layers function as antigen-presenting cell to T 
cells and inflammatory cells and work by producing IL-20, IL-23, 
and TNF-α. The proliferation of keratinocytes is stimulated by IL-20; 
proliferation of Th17 IL-17, TNF-α, IL-6, and IL-22 is promoted by 
IL-23. Keratinocytes act as pro-inflammatory cells and produce 
cytokines, such as TNF-α, IL-1, IL-6, and IL-8 [17].
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i6.31060
Review Article
13
Asian J Pharm Clin Res, Vol 12, Issue 6, 2019, 12-18
 Iriventi and Gupta 
GENETIC FACTORS
Scans of human genome explain almost nine various loci (PSORS1-9) 
which are susceptible to psoriasis. The main genetic factor of this 
disorder is PSORS-1, which consequences up to 50% of genetic 
sensitivity to psoriasis. Certain variations and changes lead to an 
increase in the risk of psoriasis, which is related to autoimmune 
diseases such as type 1 diabetes, celiac disease, Grave’s disease, and 
rheumatoid arthritis. This shows that all the above disorders have 
identical genetic factors [18].
Diagnosis
Psoriasis is diagnosed based on medical studies such as skin rash, joint 
involvement, and alterations in nails. Uncommon skin sores may occur 
rarely in patients who have to be distinguished from other clinical 
manifestations such as mycosis fungicides; seborrheic dermatitis, tinea, 
discoid lupus, and genital lesions. Careful examination of the body areas 
must be done to identify unrecognized, clinically useful characteristics. 
In some cases, a skin biopsy may be necessary. Diagnosis of psoriasis is 
easy if silvery white scales, which are filled with dark pink or red lesions 
with prominent edges, are seen. Tiny blood droplets appear under the 
scales after removing the moist skin, which is seen under pinkish moist 
tender skin. To approve the diagnosis, blood analysis and skin biopsy 
may be essential sometimes [19].
Severity of disease [20]
Based on the percentage of skin impacted, physicians generally classify 
psoriasis as mild to severe, which helps in identifying the suitable 
treatment for a patient.
• Mild: Affected body area is ˂3%
• Moderate: 3–10% skin is influenced
• Severe: ˃10% of the body is impacted.
Treating severe psoriasis is harder. Although not categorized under 
severe psoriasis, few types of psoriasis are unaffected to treatment 
which include,
• Psoriasis that is seen in the fold of the skin (inverse)
• Psoriatic arthritis




Pharmacological action of caffeine
Caffeine (1,3,7-trimethylxanthine) is a purine alkaloid and is obtained 
from coffee tree (Coffea arabica), green tea (Camellia sinensis), Cola 
acuminata, cocoa, etc. It inhibits the adenosine suppressive activity 
by showing action as a nonselective А1 and А2 adenosine receptor 
antagonist. Accumulation of cyclic adenosinmonophosphate in the 
tissues is caused by phosphodiesterase (PDE) enzyme, and it is blocked 
by this alkaloid [21].
When an imbalance occurs between the overproduction of reactive 
oxygen species (ROSs) from exogenous or endogenous source and the 
decline in antioxidant defense mechanisms, it is known as oxidative 
stress. It is discussed in the pathogenesis of aging and different human 
diseases such as neurodegenerative diseases including Alzheimer, 
Parkinson, amyotrophic lateral sclerosis (Lou Gehrig’s disease), Down’s 
syndrome, atherosclerosis, vascular disease, cancer, diabetes mellitus 
type 1 and type 2, age-related macular degeneration, and psoriatic 
arthritis [23].
Body cells are protected from damage that results from certain chemical 
reactions involving oxidation by antioxidants [22].
Antioxidant role of caffeine is linked with scavenging the hydroxyl 
radical (OH.)[24]. 1-methylxanthine and methyluric acid are the major 
metabolites of caffeine and are highly useful antioxidants [25,26] 
(Fig. 1).
Psoriasis increases the use of β-adrenergic blocking agents [26,27]. 
Catecholamine effects such as mast cell degranulation and affect 
platelet function are blocked by them [26,28].
Caffeine is a methylxanthine and has the ability to inhibit the PDE 
enzyme that hydrolyzes cyclic nucleotides. This results in higher 
concentrations of intracellular cyclic adenosine monophosphate 
(cAMP). Another proposed mechanism is the inhibition of cell surface 
receptors for adenosine [29].
Adenylate cyclase (AC), a plasma membrane-bound enzyme is activated 
through G protein coupling. This catalyzes the conversion of ATP to 
cAMP. Once a ligand bind to a G protein-coupled receptor, activation of 
AC as the heterotrimeric G protein occurs and dissociates into separate 
alpha and beta/gamma subunits (Fig. 2). The activated form of AC then 
breaks ATP to cAMP. Intracellular cAMP levels can increase 5 times 
in seconds following AC activation. cAMP-dependent protein kinases 
(e.g., protein kinase A and PKA) can also be activated by cAMP by 
altering their enzymatic activity.
There are two important types of PKA, an intracellular form and 
a membrane-bound form. On activation, both of these forms can 
move to the nucleus to phosphorylate gene regulatory proteins 
(such as cAMP response element-binding protein), which influence 
DNA transcription [30] and eventually cellular behavior. These 
effects could explain the probable therapeutic effect of caffeine in 
psoriasis. Studies showed that application of 10% caffeine produced 
significantly greater improvement in Psoriatic Area and Severity 
Index scores than placebo. The only side effect of caffeine appeared 
to be mild itching [31].
From previous studies, it is also known that caffeine also has 
proapoptotic and anti-necrotic properties due to which swelling can be 
reduced by influencing cell death pathways. As an ATM (ATM-and Rad3-
related) kinase inhibitor and ATR (ataxia-telangiectasia-mutated) 
kinase inhibitor, caffeine promotes on-time apoptosis (programmed 
cell death) of damaged cells. Caffeine also possesses anti-necrotic 
effects which prevent damage of cells due to oxidative stress from dying 
prematurely through necrosis (a process which can lead to further 
inflammation).
Fig. 1: Caffeine metabolism 65
Fig. 2: Caffeine chemical structure
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Primary treatments such as corticosteroids for atopic dermatitis and 
psoriasis are associated with side effects. As an alternate, caffeine, 
which is a cheaper, safer alternative that could harmonize the long-term 
therapy of atopic dermatitis and psoriasis patients, can be used. More 
research is needed to fully elucidate its potential [32,33].
The topical application of caffeine on plaque psoriasis was studied 
in a double-blinded placebo controlled study which demonstrated a 
significant improvement in psoriasis area and severity index in patients 
that used the topical formulation of caffeine [31].
There is an exclusive biological feature of psoriasis that leads to more 
complex interactions with caffeine, for example, with sarcomas and 
lymphoma, in which caffeine may augment the therapeutic effect 
of methotrexate [34-37]. In the case of psoriasis, alteration in the 
concentration ratio of cAMP to cyclic guanosine monophosphate in 
keratinocytes takes place [38 ]. This study led to numerous trials of 
PDE inhibitors, which showed improvement of symptoms in psoriasis 
patients [39,40]. Although succeeding trials have been not up to 
mark, PDE inhibitors are still being investigated for the treatment of 
psoriasis [41]. Any inhibitory effect of caffeine during methotrexate 
therapy is offset, in psoriasis patients, by direct effects of caffeine on 
keratinocyte cyclic nucleotides or by some other mechanism [39,42].
CHLOROGENIC ACID (CGA) AND PSORIASIS
Several polyphenols, especially chlorogenic acids (CGAs) (Fig. 3) that are 
well-known antioxidant agents, are isolated from coffee [40,43]. It is a 
group of secondary phenolic metabolites which are produced by certain 
plant species including tea, green roasted bean, coffee, berry fruits, cocoa, 
citrus fruits, apples, and pears [44,45]. CGA, a small molecular compound, 
is a biological response modifier focusing on the overall regulation and 
has a good effect on rebuilding the homeostasis of immune function. CGA 
is safe and efficient, with low recurrence rate. It has a noticeable effect on 
psoriasis, especially on plaque psoriasis and pustular psoriasis.
PHARMACOKINETICS OF CHLOROGENIC ACID (CGA)
In a different experimental model of humans and animals, CGA and its 
metabolites were evident in blood circulation [46-48]. After regular 
consumption of CGA, coffee or green coffee extract, the major CGA 
metabolites seen in the systemic circulation were ferulic, isoferulic, 
and caffeic acid. One-third of ingested CGAs in beverages and foods are 
physiologically absorbed in the small intestine which can be measured by 
high-performance liquid chromatography in the forms of 5-CQA, 4-CQA, and 
3-CQA in plasma [49,50]. The remaining two-thirds are passed into the large 
intestine where phenolic acid is further metabolized by gastrointestinal 
microflora and then absorbed [51]. The small intestine is the site where 
breakage of quinic acid from FQA (feruloylquinic acid) and CQA and then the 
release of ferulic acid and CA take place biochemically, whereas the colon 
plays a significant role in the conversion of both caffeic and ferulic acid to 
dihydroferulic acid and a major role in its absorption (Fig. 4).
MECHANISMS OF ACTION (MOA) OF CHLOROGENIC ACID (CGA)
During metabolic syndrome, CGAs exert their effective activities, and it 
is interpreted by different modes of actions. A few of these mechanisms 
are connected with CGA’s anti-inflammatory and antioxidant features. 
Oxidative stress, which is accumulated in fat, has also been proposed as 
an early initiator of the obesity-associated metabolic syndrome [53,54]. 
Chronic inflammation has been also associated with metabolic 
syndrome [48]. Another study reported that CGA treatment in mice 
fed a high-fat diet and obese mice highly decreased the expression of 
macrophage marker genes in adipose tissue such as Cd11c, Cd11b, 
Cd68, and F4/80 and pro-inflammatory mediator genes such as MCP-1 
and TNF-α in macrophages [55].
CURCUMIN AND PSORIASIS
The main ingredient and active component of turmeric are curcumin 
(dihydroferuloyl-methane), which contains two phenolic rings 
(a common structure of many flavonoids), that imparts potent 
antioxidant activities. Anti-inflammatory, antitumor, and antioxidative 
properties are exhibited by curcumin [56-59]. However, the mechanisms 
underlying these diverse effects are not yet fully understood. Cell 
proliferation arrest is caused by curcumin and apoptosis is induced 
in several types of human and animal cells. The initiated cell death 
pathway seems to depend strongly on the cell type used. TNF-α 
induces some pro-inflammatory cytokines including IL-1ß, IL-6, IL-8, 
Fig. 4: The major metabolic pathway of chlorogenic acids [52]
Fig. 3: The chemical structure of chlorogenic acid
15
Asian J Pharm Clin Res, Vol 12, Issue 6, 2019, 12-18
 Iriventi and Gupta 
and itself by activation of NF-κB or MAPKs (p38, JNK, and ERK). These 
cytokines play important roles in various inflammatory skin diseases, 
such as psoriasis [60]. Use of curcumin in the treatment of psoriasis is 
effectively based on subjective reports; however, few previous studies 
investigated its efficacy in psoriasis patients [61].
Curcumin was found to be a very potent antioxidant [62-68]. It generates 
hydroxyl radicals through the Fenton reaction by reducing Fe3+ to 
Fe2+ [66]. Effect of curcumin as superoxide scavenger was studied, 
and curcumin was found to be a potent scavenger of superoxide [67]. 
They also reported a better correlation between anti-inflammatory 
activity and superoxide scavenging property. Curcumin has the ability 
to be developed as an antipsoriatic drug due to its ability to curtail 
keratinocyte proliferation [67] and has found to be effective in the 
mouse tail animal model of psoriasis [69]. Curcumin decreases the 
expression of proinflammatory cytokines such as IL-6 and IL-8 in human 
keratinocytes [70]. These cytokines are both proinflammatory and are 
growth factors for keratinocytes. Hence, their inhibition by curcumin 
might reduce psoriasis-linked inflammation as well as psoriasis-related 
keratinocyte hyperproliferation. Moreover, HO-1 is being produced at 
higher levels in the skin of psoriatic patients and might be involved in 
heme degradation and the protection of cells from the toxic effects of 
ROSs [71]. Curcumin regulation of HO-1 and counteracting oxidative 
stress was a major highlight in its protection against scleroderma as well.
As previously reported, curcumin can be effective in treating psoriasis 
by affecting several pathogenetic pathways. Moreover, recent studies 
performed in autoimmune models suggest that curcumin can modulate 
T helper immune responses, downregulating the Th1 and Th17 cell 
pathways [66,72]. Accordingly, such activities might operate even 
in psoriasis. In fact, in a mouse model of imiquimod (IMQ)-induced 
psoriasis-like inflammation, topical curcumin was demonstrated to 
improve the skin lesions with an effect comparable to that of clobetasol 
and to significantly decrease the cutaneous levels of IL-17A, IL-17F, 
IL-22, IL-1 β, IL-6, and TNF-α mRNA [65].
There are several reasons to believe that curcumin may have potential 
for treating psoriasis. First, on irradiation with visible light, curcumin 
has been proven to be phototoxic for Salmonella typhimurium and 
Escherichia coli, even at very low concentrations [73]. This observed 
phototoxicity makes curcumin a potential photosensitizing drug, which 
could be used in phototherapy of psoriasis. Second, when curcumin was 
tested as an antipsoriatic drug in the modified mouse tail test, an animal 
model of psoriasis, it exhibited some activity [74,79]. Third, curcumin has 
been shown to inhibit the proliferation of human keratinocytes through 
suppression of pro-inflammatory pathways [58,75]. Curcumin inhibited 
the expression of TNF-α-induced IL-1 β, IL-6, TNF-α, cyclin E, MAPKs 
(JNK, p38 MAPK, and ERK), and NF-κB in HaCaT cells. Since curcumin can 
reverse the anti-apoptotic function of TNF-α in skin cells, it may have the 
potential for the treatment of psoriasis [76]. Fourth, as TNF blockers have 
been successfully used to treat psoriasis and since curcumin can block 
both the production and the action of TNF, curcumin may have potential 
as a treatment of psoriasis. Fifth, our laboratory has shown that curcumin 
is a potent inhibitor of phosphorylase kinase activity [77] the elevation in 
which has been correlated with psoriatic activity [78,79].
ANIMAL MODELS
Mouse tail test
Topical treatment of the mouse tail with antipsoriatic drugs enhances 
orthokeratotic cell differentiation in the epidermal scales. This test 
is useful for studying dermatological therapeutics that influences 
epidermal differentiation. In general, antipsoriatics such as retinoic 
acid and dithranol are induced, which produces a granular layer in the 
mouse tail epidermis (Orthokeratosis) which is a relevant parameter 
for antipsoriatic activity measurement [80].
However, the main drawback of this method is this test in its qualitative 
form is not very appropriate for screening drugs because dose-
response curves and comparisons between drugs are not possible in 
this form. Due to the lack of quantification, this model was hardly used 
for pharmacological screening in the past. At present, this problem is 
being overcome by measuring the microscopical length of the granular 
layer in a scale (Orthokeratotic differentiation) and relating it to the 
total scale length. This allows a quantitative comparison of various 
antipsoriatic drugs and can be used to construct dose-response curves 
for the individual compounds [81].
Imiquimod (IMQ)-induced murine psoriasis
In this model, psoriasis-like disease was induced to nongenetically 
modified healthy mice. They were treated daily with topical IMQ for 
6 days. This simple model shows wide characteristics described in the 
human psoriatic skin lesions. IMQ-Mu-Pso model is generated due to 
acute inflammation in the epidermis induced by IMQ, hyperactivating 
the innate immunity and leading the adaptive immunity to produce 
great amounts of IL-17. IL-17, in turn, induces angiogenesis and 
proliferation of keratinocytes, as biological characteristics of psoriatic 
lesions. IMQ-Mu-Pso also demonstrated that undisrupted molecular 
and cellular mechanisms are able to break inflammation, as mice used 
for this model are healthy mice that show the highest production of 
inflammatory cytokines on the 3rd day of treatment and show the 
highest development of psoriatic skin on the 6th day, but after this 
time, the mice are able to revert the inflammatory process as they are 
not genetically compromised. The short-lasting presence of psoriatic 
lesions is an inconvenience of this model, although it has been widely 
used to elucidate the pathogenesis of psoriasis, and very interesting 
data have been published [82].
Xenotransplantation of human skin
In xenotransplantation models, human psoriatic skin is grafted on 
the nude mice. Using T cell-deficient nude mice as recipients, the 
persistence of the psoriatic phenotype for more than 2 months after 
transplantation of lesional psoriatic skin was observed. It was suggested 
that the remaining B cells and/or murine inflammatory cytokines may 
trigger these nonspecific alterations. Depending on the purpose of the 
study, either full-thickness or split skin can be grafted from the clinically 
affected or unaffected sites of a patient, or many relevant components 
of the human skin are retained at least for several months. Dermis taken 
from clinically affected sites is overgrown by murine keratinocytes that 
subsequently form a multilayer psoriasis-like epidermis that is usually 
not seen in murine skin. The dermal compartment can thus drive 
proliferation and differentiation of the epidermis. Clinically unaffected 
skin from patients with psoriasis was grafted onto SCID mice, which 
subsequently received activated leukocytes from the same individual, 
to directly study the importance of the adaptive immune system. 
This protocol triggered the development of psoriasis in the formerly 
unaffected skin. In contrast, grafts from nonpsoriatic donors retained 
their normal phenotype even after injecting the recipient mice with 
activated leukocytes. In these experiments, grafts were derived from 
the clinically unaffected skin of either patient with psoriasis or healthy 
donors [83-87].
In vitro models for the study of psoriasis
Animal models have been very useful to dissect the molecular and 
cellular mechanisms for psoriasis development. These models have 
been also advantageous to evaluate new pharmaceuticals. Although 
humanized models have also been developed, immunodeficient 
animals are frequently used. Alternative methods such as 2D, 2D+ 
membrane, and 3D cell cultures have been developed to analyze the 
effect of new anti-psoriatic drugs [88]. 2D model consists of primary 
explants of keratinocytes or fibroblasts from psoriatic patients cultured 
over extracellular matrix proteins to evaluate cellular proliferation, 
cellular differentiation, and cytokines production [89]. In the 
2D+membrane model, two cell types are cocultured separated by a 
synthetic membrane to evaluate the interconnection between two cell 
types in the pathology [90]. 3D cultures, also known as organotypic 
culture system (OCS), allow the growth of complex biological systems 
in vitro in a way that resembles part of their normal physiology and 
function. OCSs are powerful as experimental platforms in preclinical 
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dermatological research, helping to validate mechanisms of diseases 
and to test the therapeutic potential of candidate drugs [91]. The new 
generation of 3D cultures connected to biosensors or chips allows real-
time monitoring of biological parameters such as loss of water and 
electrophysiologic parameters [92].
HERBAL CONSTITUENTS
Constituents that possess antipsoriatic activity are isolated from many 
herbal plants and used in the treatment of psoriasis.
• Capsaicin is derived from Capsicum annuum of family Solanaceae [93]
• Colchicine, an active constituent Colchicum autumnale of family 
Colchicaceae [94]
• Psoralen is derived from Psoralea corylifolia of family Fabaceae. It 
inhibits cell division by stopping epidermal DNA synthesis [87]
• Artesunate is an active constituent which is a derivative of 
Artemisinin that is processed from plant Artemisia annua L. of 
family Asteraceae. It acts by controlling the expression of CXCR2 and 
increases the secretion of TGFβ, in vitro [88]
• Koumine is derived from plant Gelsemium elegans belonging to the 
family Loganiaceae. It acts by inhibiting epidermal cell proliferation, 
promoting formation of granular cells, decreasing serum IL-2 
levels [89].
FUTURE SCOPE
There has been extensive interest in understanding and studying the 
bioactivity of caffeine and CGA associated with anti-mutagenic and 
antioxidant activities related to oxidative stress. Use of caffeine ad 
CGA in the treatment of psoriasis need to be focused more as a lot of 
research work is not available. Researchers and scientists are currently 
working to develop drug delivery systems of these constituents that can 
treat psoriasis with minimal side effects.
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